← All trials
NCT06186583
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2023
- Primary completion
- May 30, 2024
- Completion date
- Jul 30, 2024
- First posted
- Jan 2, 2024
- Last posted
- Aug 12, 2024
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abbisko Therapeutics Co, LtdLead sponsor
- Soochow UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.